API’s Are Not Magic!



No matter how much the technology improves the fundamental need for good Information Architecture will always remain. 

Read Full Article on Pivolocity Blog
I’m a proven executive with extensive experience deploying Enterprise IT solutions, Enterprise Architecture strategies and leading Digital Marketing and Sales transformations. I have held various leadership positions across the High-Tech, Telecommunications, and Health Care industries. I have deep experience with Marketing and Sales Technologies, including leading both Product Management and Engineering teams in delivering Marketing Automation, Live Chat, AI/NLP Chat Bot, Cognitive Sales Recommendation and Customer Identification and Analytic platforms.

Comments

Post a Comment

Popular posts from this blog

IBM'S MACKEY ON USING DATA, ANALYTICS TO UNDERSTAND THE FUTURE

See full Article Brian Mackey, director-IBM Marketing Transformation, is assigned to help IBM marketing deploy a data-driven strategy. His team has built a uniform system that helps the company derive actionable insights from disparate actions—Web searches, clicks, downloads and in-person events stretching across 78 countries. Mackey spoke to BtoB about how data and predictive analytics transform marketing into a customer-driven process. BtoB: How do you carve actionable insights from data? Mackey: When we started, we had all kinds of tools in place. As we went from one geography to another, marketing organizations executed and collected data in different ways. The ability to roll all of the data up and be able to understand it end-to-end—we were not in the position to do that. We deployed a common platform worldwide to manage all of the execution and standardize the way that we capture responses. Once you get that backbone in place, then you have confidence that your raw data is bein...
Read more

2019 MRD Conference

Image
I was honored to participate in the 2019 MRD Meeting in NYC hosted by the the MMRF and Memorial Sloan Kettering Cancer Center. 2019 MRD Meeting in NYC Patient Panel October 2 marked the 6th consecutive year of the Advances in Minimal Residual Disease Testing (MRD) in Myeloma roundtable meeting, a collaborative effort between Memorial Sloan Kettering Cancer Center and the MMRF. This meeting is a yearly opportunity for the myeloma community to come together to discuss the use of MRD testing in clinical practice and the progress toward its acceptance (by FDA) as a surrogate clinical endpoint for myeloma clinical trials. Attendees are a cross-section of the myeloma community, including leading myeloma physicians, pharmaceutical company representatives, scientists, and this year, for the first time, patient representatives.    All of them came prepared to debate a number of topics related to MRD measurement in myeloma. In each session, audience opinions were assess...
Read more